Publication date: Available online 13 November 2026 Source: American Heart Journal Author(s): Shao-Wei Lo, Darae Ko, Dae Hyun Kim, Long H. Ngo, Daniel E Singer, Sachin J Shah
Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial. // American Journal of Kidney Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0002870326003133?dgcid=rss_sd_all
Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial. American Journal of Kidney Diseases. https://www.sciencedirect.com/science/article/pii/S0002870326003133?dgcid=rss_sd_all
“Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial.” American Journal of Kidney Diseases.
@article{article3298,
title = {Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial},
journal = {American Journal of Kidney Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0002870326003133?dgcid=rss_sd_all}
}